
Please try another search
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic...
On Friday, Berenberg reaffirmed its Hold rating on Moderna stock (NASDAQ:MRNA) with an unchanged price target of $30.00, as shares traded near $27.03 after declining nearly 35% year-to-date. The...
Moderna Inc. reported its first-quarter 2025 earnings, revealing a narrower-than-expected loss and a decline in revenue compared to forecasts. The company posted an earnings per share (EPS) of -$2.52,...
Introduction & Market Context Moderna Inc (BMV:MRNA). (NASDAQ:MRNA) presented its first quarter 2025 financial results on May 1, showing continued revenue decline as the company transitions from...
Investing.com -- Moderna (NASDAQ:MRNA) reported a narrower-than-expected quarterly loss on Thursday, while revenue missed Wall Street estimates. The U.S. drugmaker reported a Q1 loss per share...
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review